Abstract:
Background: Manuka honey is recognized for it’s health-promoting properties and it’s use in medicine is well documented. However, the actions of Manuka honey are limited by rapid digestion and the inactivation of bioactive components such as methylglyoxal. Cyclodextrins are naturally occurring glucose rings that improve stability and bioactivity of products. This study investigates the tolerability and bioactivity of a-cyclodextrin-complexed Manuka honey called Manuka Honey with CycloPower TM. Methods: The antibacterial properties of Manuka honey complexed with a-cyclodextrin (Manuka honey with CyclopowerTM) were compared to uncomplexed Manuka honey against a range of common organisms using standard measurements of minimum inhibitory (MIC) and bactericidal (MBC) concentrations. Time course growth measurements were determined using a sublethal concentration of 2% w (honey solids)/v and measuring the area under the growth curve. Results: In tube MIC assays, Manuka honey completely inhibited Staphylococcus aureus (MSSA and MRSA), Streptococcus pyogenes, Helicobacter pylori and Moraxella catarrhalis at concentrations of 10% w/v or less, with MIC values decreasing as the methylglyoxal content of the honeys increased from 100 to 550 mg/kg. MIC values at a given methlyglyoxal level were also decreased for S. pyogenes, M. catarrhalis and H. pylori by complexing the Manuka honey with a-cyclodextrin. Pseudomonas aeruginosa was not inhibited by any of the Manuka honey or Cyclopower treatments at the concentrations tested (2-10% w/v). Manuka honey with CyclopowerTM had an increased bacteriostatic action against S. aureus, MRSA and P. aeruginosa compared with Manuka honey. Conclusions: This study concludes that Manuka honey is an effective antibacterial agent that can be enhanced by complexing with a-cyclodextrin.
